NeoStem’s AMR-001 Has Strong Chance of Success
Biotechnology stocks offer investors the opportunity for massive returns, but also carry a relatively high level of risk. Before investing in biotechnology stocks, investors should always have a strong grasp of the risk/reward opportunity. In addition to evaluating biotechnology stocks based on their fundamentals and platform, it is critical to also identify catalysts that could have a big impact on a company’s share price. One company that has a major catalyst coming up later this year is NeoStem (NASDAQ:NBS). Based upon prior data and other scientific research, NeoStem is likely to demonstrate efficacy in its AMR-001 Phase 2 trial.
NeoStem is a biotechnology company focused on the discovery, development and commercialization of novel proprietary cellular therapy products. The company also operates a contract development and manufacturing organization that provides services for the regenerative medical industry. Although the company is building a platform with several critical technologies, the one that investors are likely keeping their eyes on is Amorcyte AMR-001, which is used in the prevention of major adverse cardiac events that can develop after acute myocardial infarction.
In late December, NeoStem announced completion of enrollment in its PreSERVE AMI study. PreSERVE AMI is a randomized, double-blind placebo-controlled Phase 2 clinical trial that is evaluating AMR-001 for the treatment of patients with left ventricular dysfunction following acute ST segment elevation myocardial infarction (or, STEMI). The primary endpoint of the trial will be increased cardiac perfusion at baseline and 6 months. The secondary endpoints will include quality of life measures and the safety profile. In the same announcement, NeoStem also told investors that it expects to reveal the final data during the third quarter later this year.